Metastat Inc.

Metastat Inc. is a biotechnology and molecular diagnostics company specializing in the development of advanced testing solutions for cancer care. The company’s primary focus is on creating diagnostic assays that help oncologists and patients better assess the risk of systemic metastasis and make informed decisions regarding adjuvant chemotherapy. Its core technologies, MetaSite Breast and MenaCalc, are designed to provide clinically actionable information by analyzing the biological pathways involved in metastatic disease, particularly in epithelial-based solid tumors. The MetaSite Breast assay is tailored for early-stage invasive breast cancer patients, offering insights that support personalized treatment. MenaCalc is a quantitative immunofluorescence platform applicable to a broad spectrum of cancers, including breast, lung, colorectal, and prostate. By targeting molecular drivers of metastasis, Metastat Inc. aims to address critical gaps in cancer diagnostics and prognosis, serving as a key player in the precision medicine landscape and the broader pharmaceuticals and life sciences sector.